GSK Nov 2024 50.000 call
| Previous close | 0.3500 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 50.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.3500 - 0.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 240 |
- Yahoo Finance Video
GSK stock sinks after court allows Zantac lawsuits to proceed
Shares of Britain-based pharmaceutical company GSK plc (GSK) — formerly known as GlaxoSmithKline — are sliding in pre-market trading and into Monday's session open following a court ruling that has approved more than 70,000 lawsuits to go forward over heartburn medication Zantac's alleged links to cancer. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
Evening StandardFTSE 100 Live 3 June: New York trading glitch sparks volatility, GSK shares tumble
GSK shares are today’s major focus after the drugs giant’s defence against Zantac claims suffered a setback in a Delaware court. The FTSE 100 index is trading higher after Friday’s late rally by Wall Street markets was further boosted by this week’s prospect of an ECB interest rate cut. Other companies in the spotlight today include FTSE 250-listed Hollywood Bowl, having posted an 11% rise in half-year profits.
BenzingaGSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex for relapsed or refractory multiple myeloma. The data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On the primary endpoint of progression-free survival (PFS), the belantamab mafodotin comb
